Structure-Based Drug Discovery: A Case Study with RIPK1

Overview

Structure-based drug discovery (SBDD) is a widely used computational approach that leverages the three-dimensional structure of biological targets to identify and optimize potential drug candidates. In this introductory tutorial, we present a real-world case study using Receptor-Interacting Protein Kinase 1 (RIPK1)—a clinically relevant target involved in inflammation, neurodegeneration, and cell death pathways.

This post is designed for students and early-career researchers who are interested in computational drug discovery and want to understand the overall workflow without being overwhelmed by technical complexity. Future posts from Idgence Research will provide step-by-step hands-on tutorials covering each stage in detail.

Why RIPK1?

RIPK1 is a serine/threonine protein kinase that plays a central role in regulating cell survival, inflammation, and necroptosis. Dysregulation of RIPK1 has been linked to several diseases, including neurodegenerative disorders and inflammatory conditions.

Protein-Ligand crustal structure, Cartoon
Protein-Ligand crustal structure, Mesh

RIPK1 has also been the focus of multiple peer-reviewed computational studies, making it an excellent example for demonstrating structure-based drug discovery workflows.

Case Study Background

In previous studies, we investigated RIPK1 inhibition using computational approaches such as virtual screening, molecular docking, and molecular dynamics simulations:

These studies form the scientific foundation for the simplified workflow presented here.

Protein Structure Preparation

A critical requirement for structure-based drug discovery is a reliable three-dimensional structure of the target protein.

  • We initially downloaded the X-ray crystal structure of human RIPK1 from the RCSB Protein Data Bank (PDB ID: 6NYH, resolution 2.10 Å).
  • This structure contains unmodelled and partially modelled residues, which can affect downstream analysis.
  • To address this, a template-based homology model of the RIPK1 kinase domain was generated using the SWISS-MODEL webserver:
    https://swissmodel.expasy.org/

Future tutorials will explain protein structure cleaning, validation, and refinement in detail.

Key Steps in Structure-Based Drug Discovery

1. Target Identification

Select a disease-relevant protein with biological and clinical significance (e.g., RIPK1).

2. Protein Structure Preparation

Obtain and refine a reliable 3D structure using experimental data or homology modeling.

3. Ligand Selection

Compile small molecules from natural products or chemical libraries for screening.

4. Molecular Docking

Predict how ligands bind to the protein’s active site using docking software.

5. Molecular Dynamics Simulation

Evaluate the stability of protein–ligand complexes over time.

6. Result Interpretation

Analyze binding modes, stability, and interaction patterns to prioritize candidates.

Learning and Research at Idgence Research

Idgence Research integrates computational tools, interdisciplinary expertise, and training to support modern scientific discovery.

What’s Next?

This post provides a conceptual overview of structure-based drug discovery using RIPK1 as an example. Upcoming tutorials from Idgence Research will cover:

  • Protein preparation (hands-on)
  • Docking workflows with AutoDock Vina
  • Molecular dynamics simulations using GROMACS
  • Binding free energy analysis
  • Best practices and common pitfalls

Stay connected with Idgence Research to explore these topics step by step.

Similar Posts